Frazier Lifesciences Acquisition (FLACU) Stock Price, News & Analysis

Company Overview

Frazier Lifesciences Acquisition Corp (OTCMKTS: FLACU) is a special purpose acquisition company (SPAC) sponsored by Frazier Healthcare Partners, a leading healthcare investment firm. The company completed its initial public offering in 2021, raising capital through a trust to pursue a business combination in the life sciences sector. As a blank‐check vehicle, FLACU seeks to merge with or acquire one or more operating businesses that develop, manufacture or commercialize products and technologies in biotechnology, pharmaceuticals, medical devices and related healthcare services.

FLACU’s primary objective is to leverage the depth of Frazier Healthcare Partners’ sector expertise and deal-sourcing capabilities to identify high-growth targets across North America and select global markets. The SPAC’s investment strategy focuses on therapeutic innovation, specialty drug development and advanced medical technologies, with an emphasis on companies that address significant unmet medical needs. By combining public capital with Frazier Healthcare Partners’ operational guidance, FLACU aims to accelerate value creation for shareholders and portfolio companies alike.

The company’s leadership team comprises seasoned professionals from Frazier Healthcare Partners, bringing decades of experience in life sciences investing, corporate development and operational management. While FLACU itself does not conduct operating activities beyond pursuing its initial business combination, it benefits from the sponsor’s track record of building and supporting healthcare companies through growth-stage financing, strategic partnerships and exit planning.

Upon closing a qualifying transaction, Frazier Lifesciences Acquisition Corp intends to transition from a SPAC structure to a publicly listed operating company, providing investors with transparent ownership in an established life sciences business. Until a combination is completed, the company’s cash resources remain in trust, preserving capital for deployment in pursuit of its acquisition objectives.

Key Stats

• Today's Range: $8.07 to $10.80
• 50-Day Range: $9.50 to $9.50
• 52-Week Range: $8.07 to $10.80
• Volume: 18,300 shs
• Average Volume: 13,949 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FLACU Stock Analysis - Frequently Asked Questions

How have FLACU shares performed this year?

Frazier Lifesciences Acquisition's stock was trading at $9.50 at the beginning of 2025. Since then, FLACU stock has increased by 0.0% and is now trading at $9.50.

How do I buy shares of Frazier Lifesciences Acquisition?

Shares of FLACU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Financial Services
• Industry: Shell Companies
• Sub-Industry: Trading
• Current Symbol: OTCMKTS:FLACU
• CIK: 1828326
• Web: www.frazierlifesciencesacquisition.com
• Phone: 206 621 7200
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A